May 24, 2024
YS Biopharma Announces Name Change to LakeShore Biopharma
May 21, 2024
YS Biopharma Announces Results of Extraordinary General Meeting
May 07, 2024
YS Biopharma to Hold Extraordinary General Meeting on May 21, 2024 and Announces the Appointment of Interim Chief Executive Officer
Apr 29, 2024
YS Biopharma Receives Additional 180 Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule
Apr 19, 2024
YS Biopharma Announces Unaudited Financial Results for the First Nine Months of Fiscal Year 2024
Apr 18, 2024
YS Biopharma Granted Phase I Clinical Trial License of Therapeutic Chronic Hepatitis B Virus Vaccine
Apr 09, 2024
YS Biopharma Announces Positive Interim Results of Pivotal Phase 3 Clinical Study of PIKA Rabies Vaccine
Apr 03, 2024
YS Biopharma Announces Full Repayment of US$40,000,000 Loan Facility
Mar 05, 2024
YS Biopharma Announces Board Changes and Strategic Leadership Appointments in Chinese Subsidiaries
Feb 22, 2024
YS Biopharma Announces Results of Extraordinary General Meeting held on February 22, 2024
Feb 16, 2024
YS Biopharma Announces Results of Extraordinary General Meeting and Responds to False Statements about the Meeting
Feb 14, 2024
YS Biopharma to Hold an Extraordinary General Meeting on February 22, 2024 pursuant to a Shareholder Requisition to Enhance Corporate Governance
Feb 14, 2024
YS Biopharma Announces Appointment of New Directors
Feb 12, 2024
YS Biopharma Responds to a Notice of Extraordinary General Meeting of Shareholders of YS Biopharma Co., Ltd.
Feb 09, 2024
YS Biopharma Announces US$40 Million Private Placement Financing
Jan 22, 2024
YS Biopharma Announces Unaudited Financial Results for the First Half of Fiscal Year 2024
Jan 08, 2024
YS Biopharma Announces Changes to its Board Committees